0000000000550441
AUTHOR
Lori Berard
showing 2 related works from this author
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
2017
BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…
Patient‐reported outcomes in adults with type 1 diabetes in global real‐world clinical practice: the SAGE study
2021
International audience; Aims: This secondary analysis of the SAGE study aimed to evaluate the association between glycaemic control and patient-reported outcomes (PROs), in adults with type 1 diabetes (T1DM) across different age groups and regions.Materials and methods: SAGE was a multinational, cross-sectional, observational study in adults with T1DM. Data were collected at a single visit, analysed according to predefined age groups (26-44, 45-64, and ≥65 years), and reported across different regions. PRO questionnaires were applied to assess hypoglycaemia fear (Hypoglycemia Fear Survey-II [HFS-II]), diabetes-related distress (Problem Areas In Diabetes [PAID]), insulin treatment satisfacti…